Wetenschappelijke publicaties
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Huiberts AJ, Hoeve CE (Conformité Européenne), de Gier B, Cremer J, van der Veer B, de Melker HE, et al.
Eurosurveillance 2024;29(10)
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJM, den Hartog G, et al.
International Journal of Infectious Disease. 2023;133:36-42
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJ, den Hartog G, et al.
Eurosurveillance. 2023;28(7)
Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
de Gier B, Huiberts AJ, Hoeve CE, den Hartog G, van Werkhoven H, van Binnendijk R, et al.
Nature communications 2023;14(1):4793
Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
Hoeve CE, de Gier B, Huiberts AJ, de Melker HE, Hahne SJM, van den Hof S, Knol MJ
Journal of Infectious Diseases 2023;228(4):431-8
Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
den Hartog G, Andeweg SP (Sustainable Procurement), Hoeve CE, Smits G, Voordouw B, Eggink D, et al.
Scientific reports. 2023;13(1):18394
COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study
Hoeve CE, Huiberts AJ, de Gier B, Andeweg SP, den Hartog G, de Melker HE, et al.
MedRxiv. 2023 (preprint)
Association between common adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations in a population-based prospective cohort study in the Netherlands
Holwerda MR (antimicrobial resistance), Hoeve CE, Huiberts AJ, den Hartog G, de Melker HE, Van den Hof S, Knol MJ.
MedRxiv. 2023 (preprint)
Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO)
Huiberts AJ, Kooijman MN, de Melker HE, Hahne SJ, Grobbee DE, Hoeve CE, et al.
ResearchSquare. 2022 (preprint)
Rapportages
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2022-2023.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2023. RIVM rapport 2023-0330
Hoofdstuk 9
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2021-2022.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2022. RIVM rapport 2021-0042
Hoofdstuk 9
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2020-2021.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2021. RIVM rapport 2021-0055
Hoofdstuk 9